SUVN 911

Drug Profile

SUVN 911

Alternative Names: SUVN911

Latest Information Update: 26 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Suven Life Sciences
  • Class Antidepressants
  • Mechanism of Action Alpha4beta2 nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Major depressive disorder

Most Recent Events

  • 01 May 2017 Phase-I clinical trials in Major depressive disorder (In volunteers) in USA (PO)
  • 15 Nov 2011 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Major depressive disorder presented at the 41st Annual Meeting of the Society for Neuroscience (SfN-2011)
  • 21 Oct 2009 Preclinical trials in Major depressive disorder in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top